-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
-
Summary
-
CRISPR Therapeutics AG quarterly/annual General and Administrative Expense history and growth rate from 2014 to 2024.
- CRISPR Therapeutics AG General and Administrative Expense for the quarter ending December 31, 2024 was $18.1M, a 9.98% increase year-over-year.
- CRISPR Therapeutics AG General and Administrative Expense for the twelve months ending December 31, 2024 was $73M, a 4.18% decline year-over-year.
- CRISPR Therapeutics AG annual General and Administrative Expense for 2024 was $73M, a 4.18% decline from 2023.
- CRISPR Therapeutics AG annual General and Administrative Expense for 2023 was $76.2M, a 25.7% decline from 2022.
- CRISPR Therapeutics AG annual General and Administrative Expense for 2022 was $102M, a 2.78% increase from 2021.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Annual (USD)
General and Administrative Expense, YoY Annual Growth (%)